CymitQuimica logo

CAS 1650550-25-6

:

Enasidenib (mesylate)

Description:
Enasidenib (mesylate) is a small molecule inhibitor primarily used in the treatment of acute myeloid leukemia (AML) with specific genetic mutations. It functions as a selective inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme, which plays a crucial role in cellular metabolism and differentiation. By inhibiting IDH2, Enasidenib alters the metabolic pathways within cancer cells, leading to the accumulation of oncometabolites and promoting differentiation of leukemic cells. The mesylate salt form enhances its solubility and stability, facilitating its administration. Enasidenib is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Common side effects may include nausea, fatigue, and potential differentiation syndrome, which requires monitoring. Its development represents a significant advancement in targeted cancer therapies, particularly for patients with IDH2 mutations, providing a more personalized approach to treatment. As with any medication, its use should be guided by a healthcare professional, considering the specific clinical context and patient characteristics.
Synonyms:
  • 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol methanesulfonate
  • AG-221 mesylate
  • AG-221 salt
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.